A 59-year-old woman with metastatic endometrioid endometrial carcinoma, mismatch repair proficient, is planned for first-line systemic chemotherapy. Which regimen is the standard backbone of treatment?
- A Cisplatin plus bleomycin plus etoposide
- B Carboplatin plus paclitaxel ✓
- C Doxorubicin plus ifosfamide
- D Gemcitabine plus docetaxel
Correct answer: B. Carboplatin plus paclitaxel
Explanation
Carboplatin plus paclitaxel is the accepted first-line doublet for advanced or recurrent endometrial carcinoma, offering comparable efficacy to doxorubicin-cisplatin with a more tolerable toxicity profile. Cisplatin, bleomycin and etoposide is a germ cell regimen, doxorubicin with ifosfamide treats soft tissue sarcoma, and gemcitabine with docetaxel is used in leiomyosarcoma. Immunotherapy is added based on dMMR or MSI-H status but does not replace the platinum-taxane backbone.
Reference: Berek and Novak's Gynecology, 16th ed.
High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP
Written and medically reviewed by the StethoPrep medical team.